Solid Lipid Nanoparticles: A Comparative Review

Yash Agrawal, Sandip Prashad Tiwari, Rashmi Sinha*

Faculty of Pharmacy, Kalinga University, Naya Raipur, Chhattisgarh, India (492101)

ABSTRACT

Solid Lipid Nanoparticles (SLNs) represent a modern, versatile platform for drug delivery, merging the safety of physiological lipids with the precision of nanoscale engineering. This comprehensive overview explores the journey of SLNs from their structural design and formulation methods to their therapeutic applications and future potential. Key advantages-such as biocompatibility, controlled release, and improved drug stability—are weighed against challenges like limited drug loading, scale-up difficulties, and regulatory ambiguity. Emerging innovations such as nanostructured lipid carriers (NLCs), surface functionalization, and stimuli responsive systems show promise in overcoming current barriers. Applications of SLNs now span across oncology, neurology, and vaccine delivery and even extend beyond medicine into fields like agriculture and environmental science. With ongoing research and technological advancements, SLNs are poised to play a significant role in personalized medicine, theragnostic, and industrial nanotechnology. This review aims to offer both a technical foundation and a forward-looking perspective on how these tiny lipid-based systems may shape the future of therapeutics and beyond.

Keywords:

Solid Lipid Nanoparticles (SLNs), Lipid-based drug delivery, Drug delivery systems, Biocompatible carriers

1. INTRODUCTION

In the world of pharmaceuticals, delivering a drug effectively is just as crucial as the drug itself. Traditional forms like pills, syrups, and injections often fall short when it comes to delivering the right amount of medicine to the right place in the body at the right time. These methods face many challenges, such as poor solubility of drugs, low bioavailability, rapid breakdown in the body, and unwanted side effects. To overcome these issues, scientists turned to nanotechnology, which led to the development of Solid Lipid Nanoparticles (SLNs). SLNs are tiny, fat-based particles that remain solid at room and body temperature. They are capable of encapsulating drugs, protecting them from damage, and releasing them in a controlled and targeted way. Their small size helps them navigate through the body efficiently, even reaching tough areas like the brain. This introduction sets the stage for understanding why SLNs are considered one of the most promising advancements in drug delivery.

2. Historical Background and Development of SLNs

The concept of SLNs came into focus in the early 1990s when researchers sought better drug delivery systems. Older methods like liposomes and polymeric nanoparticles had limitations such as instability, toxicity, and poor control over drug release. SLNs were introduced as a safer, more stable alternative. Created using naturally safe fats, these particles combined the benefits of earlier systems while avoiding their problems. Scientists explored various lipids and surfactants to create more effective formulations, and by the 2000s, SLNs were being tested for drugs treating cancer, infections, and inflammation. Their ability to hold both water- and fat-soluble drugs made them extremely versatile. The discovery of Nanostructured Lipid Carriers (NLCs)—an advanced version of SLNs—further improved drug loading and stability. Today, SLNs are used beyond medicine in cosmetics and agriculture, marking a major evolution in how we think about delivering active ingredients.

3. Composition and Preparation Techniques

3.1 What SLNs Are Made Of

SLNs are made using a combination of solid lipids, surfactants (also known as emulsifiers), and the active drug. The solid lipids act as the main body that holds the drug, while surfactants keep the particles stable and prevent them from clumping. Additional components like co-surfactants, charge modifiers, or targeting agents can also be added to improve performance. For example, if a drug needs to reach cancer cells specifically, a targeting molecule can be added to the SLN's surface. The goal in designing SLNs is to make sure they are safe, stable, and effective at delivering their cargo exactly where it's needed.

I. Solid Lipids: -
II. Surfactants
III. Active Pharmaceutical Ingredient (API)
IV. Optional Additives

3.2 How SLNs Are Made

Depending on the drug and its sensitivity, SLNs can be made using several methods, such as high-pressure homogenization, solvent evaporation, or the microemulsion technique. Each method has its strengths—some are better for heat-sensitive drugs, while others are ideal for large-scale production. Choosing the right preparation method depends on the drug's properties and the desired outcome. Understanding these techniques allows scientists to tailor SLNs to specific medical needs.

I. High-Pressure Homogenization (HPH)
II. Solvent Emulsification–Evaporation
III. Microemulsion Method
IV. Ultrasonication or High-Shear Mixing
V. Double Emulsion (W/O/W)

4. Characterization of SLNs

4.1 Particle Size and Size Distribution

The first thing scientists assess is the size of the SLNs, because smaller particles generally absorb better and pass through biological barriers more easily. Uniform size distribution, measured by a low polydispersity index (PDI), is critical for stability.

4.2 Zeta Potential (Surface Charge)

This indicates the electrical charge on the particle surface, which affects stability in suspension. High zeta potential means the particles repel each other, reducing clumping.

4.3 Morphology and Surface Characteristics

These are studied using microscopy to visualize shape, smoothness, and structural integrity—factors that influence how SLNs behave in the body.

4.4 Drug Loading and Entrapment Efficiency

These values show how much of the drug is inside the SLNs. High efficiency ensures less waste and more effective treatment.

4.5 Crystallinity and Polymorphism

Analysing the internal structure of the lipids helps predict drug release and stability over time.

4.6 In Vitro Drug Release

These simulate how the drug will release from SLNs in the body under controlled conditions, providing essential insight into effectiveness.

4.7 Stability Studies

Long-term tests show how well SLNs retain their properties under different storage conditions, ensuring shelf-life and reliability.

5. Mechanism of Drug Release

5.1 Drug Incorporation Models within SLNs

The drug can be placed in different parts of the SLN—throughout the matrix, in the core, or near the shell. Each placement affects how the drug is released.

I. Homogeneous Matrix
II. Drug-Enriched
III. Drug-Enriched

5.2 Primary Mechanisms of Drug Release

Drugs may be released slowly through diffusion, by the breakdown (erosion) of the lipid, or when triggered by specific conditions like changes in pH or temperature. These smart mechanisms allow SLNs to act like responsive medicine carriers.

I. Diffusion-Controlled Release
II. Erosion or Degradation of the Lipid Matrix
III. Osmotically or pH-Triggered Release

5.3 Factors Influencing Drug Release

Lipid type, particle size, compatibility between the drug and lipid, surfactant type, and external factors like temperature all influence release timing.

I. Lipid Type and Concentration
II. Particle Size
III. Drug-Lipid Compatibility
IV. Surfactant Type:
V. External Conditions

5.4 Mathematical Modelling of Release Kinetics

To predict and fine-tune the release behavior, drug scientists often use mathematical models.

I. Zero-order model
II. First-order model
III. Higuchi model
IV. Korsmeyer-Peppas model

6. Advantages of Solid Lipid Nanoparticles (SLNs)

I. Biocompatibility & Biodegradability

SLNs are made from natural lipids that are recognized and easily broken down by the body. This reduces the risk of harmful side effects and makes them safer for long-term use.

II. Controlled and Sustained Drug Release

They release drugs gradually over time instead of all at once. This helps maintain steady drug levels in the body, reduces side effects, and allows less frequent dosing.

III. Improved Drug Stability

SLNs protect fragile drugs from damage caused by light, heat, or enzymes, helping them last longer and work more effectively.

IV. Hydrophilic & Lipophilic Drug Compatibility

They can carry both hydrophilic (water-loving) and lipophilic (fat-loving) drugs, making them versatile for many treatments.

V. Enhanced Bioavailability.

Their small size increases the surface area for absorption, helping more of the drug get into the bloodstream where it can work.

VI. Protection from Degradation

SLNs shield sensitive drugs—like proteins and peptides—from enzyme breakdown, which can improve effectiveness and allow for oral delivery instead of injections.

7. Limitations and Challenges

I. Limited Drug Loading Capacity

One of the main limitations of SLNs is their relatively low drug loading capacity. Because they are made from solid lipids, there is limited space for incorporating high doses of some drugs. This means SLNs might not be suitable for delivering drugs that require large doses or that do not blend well with the lipid core.

II. Drug Expulsion During Storage Over time,

Over time, the structure of the lipid matrix can change, particularly during storage. This may lead to the drug being pushed out of the nanoparticles—a process known as drug expulsion. This affects the stability and reliability of the formulation.

III. Polymorphic Transitions of Lipids

SLNs can undergo polymorphic transitions, where the internal structure of the lipid changes from one crystalline form to another. These transitions can influence drug release, drug retention, and overall performance.

IV. Particle Growth and Aggregation

If SLNs are not stabilized properly, they can clump together or grow in size over time, which affects their bioavailability and drug delivery efficiency. Proper formulation and surfactant choice are critical to avoid this issue.

V. Difficulty in Encapsulating Hydrophilic Drugs

Sterilization is essential for any product that will be injected or applied to sensitive areas. However, common sterilization techniques like heat or radiation can damage SLNs or cause drug leakage, presenting a major production challenge.

VI. Complexity in Large-Scale Production

While SLNs are easy to prepare on a small scale in the lab, scaling up the process for industrial-level production can be complicated and expensive. Consistency, quality control, and cost-effectiveness must all be carefully managed.

8. Applications of Solid Lipid Nanoparticles (SLNs)

8.1 Cancer Drug Delivery

SLNs are increasingly being used in cancer treatment due to their ability to deliver chemotherapy drugs directly to tumour cells. By modifying their surface with ligands or antibodies, SLNs can recognize and bind to cancer cells specifically, minimizing harm to healthy tissues. This targeted approach reduces side effects and increases the effectiveness of treatment.

8.2 Brain Targeting

One of the biggest challenges in medicine is delivering drugs across the blood-brain barrier (BBB). SLNs have shown promise in overcoming this barrier. Their small size and ability to be modified with targeting agents allow them to carry drugs into the brain, making them suitable for treating neurological diseases like Alzheimer’s, Parkinson’s, and brain tumours

.

8.3 Oral Drug Delivery

Many drugs are destroyed by stomach acid or enzymes before they can work. SLNs protect these drugs and improve their absorption in the intestines. This is especially useful for drugs that have poor water solubility or are unstable in the digestive system. SLNs also enhance the bioavailability of these drugs, making oral dosing more effective.

8.4 Topical Drug Delivery

In skincare and wound healing, SLNs are used in creams and gels to improve drug penetration through the skin. They provide a controlled release, moisturize the skin, and protect the active ingredients. SLNs are also used in cosmetics to deliver vitamins and antioxidants more effectively.

8.5 Vaccine and Protein Delivery

Delivering drugs to the eyes is difficult because of barriers like blinking and tear production. SLNs help in prolonging drug residence time in the eye and improve penetration into deeper layers, making them ideal for treating conditions like glaucoma and eye infections.

9. Recent Advances in Solid Lipid Nanoparticles (SLNs)

9.1. From SLNs to Nanostructured Lipid Carriers (NLCs): A Smarter Structure

To improve the limitations of early SLNs, scientists developed NLCs by blending solid and liquid lipids. This allows for better drug loading, reduces drug expulsion during storage, and enhances long-term stability. NLCs maintain the core strengths of SLNs while offering a more flexible internal structure, making them ideal for modern drug delivery needs.

9.2. Surface Functionalization: Targeting Made Personal

Advanced SLNs are now being coated or attached with specific molecules like ligands, antibodies, or polymers. These modifications help the SLNs identify and bind to target cells (such as cancer or infected cells), making treatment more efficient while reducing damage to healthy tissues. This approach is widely used in personalized medicine.

This kind of customization is like adding GPS to a delivery van — it ensures the package reaches exactly the right destination.

9.3. Co-Delivery Systems: Teamwork for Better Therapy

Cutting-edge research has led to SLNs that respond to specific triggers like pH, temperature, or enzymes. These smart nanoparticles release their drug load only when they encounter certain conditions, such as the acidic environment of a tumour. This minimizes premature drug release and ensures the drug works where it's needed most.

9.4. Responsive SLNs: Smart Delivery on Demand

Some SLNs are now designed to carry more than one drug at a time—called co-delivery systems. This is especially useful in diseases like cancer or HIV, where multiple drugs are needed. These systems help improve patient compliance, simplify treatment, and increase therapeutic success.

9.5. Scaling Up: Making It Work in the Real World

Researchers are combining SLNs with other nanocarriers (like polymers or micelles) to create hybrid systems. These hybrids combine the best features of different delivery methods, improving drug stability, loading capacity, and targeting precision.

10. Future Prospects of Solid Lipid Nanoparticles (SLNs)

10.1. Personalized Medicine:

As healthcare moves toward personalization, SLNs are expected to play a crucial role. Future SLNs can be engineered to carry drugs tailored to a patient's specific genetic makeup, lifestyle, or disease stage. With advanced targeting capabilities, SLNs will be able to deliver drugs with pinpoint accuracy, especially in diseases like cancer, where cells vary greatly from person to person.

10.2. Theragnostic: When Treatment Meets Real-Time Diagnosis

Theragnostic SLNs combine therapy and diagnostics in a single system. These specialized SLNs can carry both a drug and an imaging agent, allowing doctors to see where the medicine is going and how well it's working in real-time. This could revolutionize how treatments are monitored and adjusted on the spot.

10.3. Expanding Horizons: SLNs Beyond Medicine

Beyond pharmaceuticals, SLNs show promise in other sectors like food, agriculture, and

cosmetics. In agriculture, they can deliver nutrients or pesticides more safely and effectively. In the food industry, SLNs could be used to carry Flavors, nutrients, or preservatives that improve product stability and shelf life.

10.4. Interrogation with Artificial Intelligence AI

AI can significantly aid the development of smarter SLNs. By analysing huge datasets, AI could help design better lipid combinations, predict drug release behaviour, and even customize treatment plans. This fusion of AI with nanotechnology will likely push SLNs into the next era of drug delivery.

CONCLUSION

Solid Lipid Nanoparticles (SLNs) represent a transformative advancement in the field of drug delivery. They offer a unique blend of safety, effectiveness, and versatility, owing to their biocompatible lipid matrix and nano-sized structure. SLNs solve many issues faced by traditional delivery methods, such as poor drug solubility, rapid degradation, and uncontrolled release. They can carry a wide range of drugs and offer controlled, targeted delivery to specific body sites, thereby improving therapeutic outcomes and reducing side effects. Throughout this review, the composition, mechanisms, benefits, challenges, and diverse applications of SLNs have been explored in detail. While SLNs already play a valuable role in modern medicine, ongoing research continues to refine their design and expand their uses—including in cancer treatment, brain targeting, and personalized medicine. Despite some limitations, such as drug loading and stability concerns, advancements like NLCs, stimuli-responsive systems, and co-delivery models are steadily addressing these gaps. Looking ahead, SLNs hold immense promise not only in pharmaceuticals but also in sectors like food, agriculture, and cosmetics. Their adaptability and ongoing innovation solidify their status as a cornerstone in the future of smart drug delivery systems.

REFERENCE

1. Vyas SP, Khar RK. Targeted and Controlled Drug Delivery: Novel Carrier Systems. CBS Publishers; 2017.

2. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818–22.

3. Müller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 2004;113(1–3):151–70.

4. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145–60.

5. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161– 77.

6. Jenning V, Gohla SH. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul. 2001;18(2):149–58.

7. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2–3):165–96.

8. Ekambaram P, Sathali AAH, Priyanka K. Solid lipid nanoparticles: a review. Scientific Reviews and Chemical Communications. 2012;2(1):80–102.

9. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1–2):170–84.

10. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257–72.

11. Shah R, Eldridge D, Palombo E, Harding I. Optimisation and stability assessment of solid lipid nanoparticles using particle size and zeta potential. J Phys Sci. 2014;25(1):59–75.

12. Souto EB, Müller RH. Cosmetic features and applications of lipid nanoparticles (SLN®, NLC®). Int J Cosmet Sci. 2008;30(3):157–65.

13. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and

applications. Adv Drug Deliv Rev. 2001;47(2–3):165–96.

14. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161– 77.

15. Jenning V, Gohla SH. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul. 2001;18(2):149–58.

16. Souto EB, Müller RH. Lipid nanoparticles (SLN, NLC) for cosmetic, dermal, and transdermal applications. Drug Dev Ind Pharm. 2008;34(12):1325–31.

17. Ekambaram P, Sathali AAH, Priyanka K. Solid lipid nanoparticles: a review. Scientific Reviews and Chemical Communications. 2012;2(1):80–102.

18. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in pharmaceutical and cosmetic products. Int J Pharm. 2009;366(1–2):170–84.

19. Shah R, Eldridge D, Palombo E, Harding I. Optimization and stability assessment of solid lipid nanoparticles using particle size and zeta potential. J Phys Sci. 2014;25(1):59–75.

20. Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242(1–2):121–8.